tuberculosi
tb
caus
infect
mycobacterium
tuberculosi
mtb
lead
caus
death
due
infecti
diseas
claim
million
live
global
year
rise
strain
mtb
resist
almost
avail
tb
drug
make
deadli
infecti
diseas
omin
moreov
one
third
world
popul
harbor
mtb
latent
state
serv
larg
reservoir
individu
potenti
risk
develop
activ
diseas
spread
easili
remain
popul
current
bacil
calmetteguerin
bcg
develop
nearli
year
ago
avail
vaccin
prevent
tb
bcg
remain
wide
administ
vaccin
around
world
effect
provid
protect
childhood
extrapulmonari
form
tb
benefici
effect
vaccin
given
children
wane
time
bcg
afford
highli
inconsist
inadequ
protect
pulmonari
tb
ineffect
given
adulthood
bcg
minim
effect
pulmonari
tb
major
effect
global
burden
tb
reason
vari
protect
efficaci
bcg
still
unclear
thought
preexposur
environ
mycobacteria
may
prevent
mask
protect
immun
induc
bcg
also
bcg
strain
lost
gene
encod
immunodomin
antigen
attenu
howev
consid
fact
bcg
administ
billion
infant
countriesset
high
incid
tb
continu
forese
futur
develop
new
effici
vaccin
replac
bcg
formid
task
therefor
improv
boost
supplement
bcg
differ
clinic
set
appear
logic
path
new
vaccineimmunotherapi
approach
tb
attempt
improv
efficaci
bcg
vaccin
phase
clinic
trial
safeti
toler
conduct
use
recombin
bcg
express
immunodomin
antigen
seen
activ
infect
reactiv
latenc
b
mutant
perfringolysin
deriv
clostridium
perfringen
abl
perfor
endosom
membran
howev
unknown
reason
patient
develop
reactiv
varicella
zoster
viru
result
discontinu
develop
vaccin
heterolog
primeboost
strategi
use
viralvector
vaccin
adjuv
proteinpeptid
subunit
vaccin
hope
approach
tb
vaccin
sever
viral
vector
adenoviru
human
human
chimp
vesicular
stomat
viru
vsv
modifi
vaccinia
ankara
mva
express
antigen
highli
conserv
molecul
across
mycobacteri
speci
shown
provid
superior
protect
administ
bcgprime
anim
compar
bcg
alon
howev
despit
highli
immunogen
none
experiment
vaccin
provid
satisfactori
result
clinic
test
yet
recombin
fusion
proteinbas
vaccin
may
potenti
booster
bcg
vaccin
may
also
possess
number
advantag
high
level
safeti
puriti
costeffect
howev
vaccin
would
requir
effect
safe
adjuv
strengthen
immun
respons
gener
fusion
proteinbas
vaccin
test
clinic
trial
includ
fusion
protein
three
tuberculosi
antigen
formul
proprietari
adjuv
valneva
recombin
fusion
protein
mtb
antigen
combin
adjuv
immunogen
fusion
protein
deriv
two
tuberculosi
antigen
glaxosmithklin
proprietari
adjuv
efficaci
experiment
vaccin
remain
determin
earli
secret
antigen
target
kda
protein
potent
tcell
antigen
express
pathogen
mtb
contain
unusu
high
number
permiss
cell
epitop
span
entir
sequenc
molecul
interest
antigen
associ
activ
mtb
infect
howev
gene
encod
belong
region
bcg
vaccin
strain
distribut
worldwid
delet
region
base
subunit
vaccin
shown
tremend
potenti
anim
model
earlier
report
lipopeptid
antigen
correspond
immunodomin
epitop
promis
candid
tb
vaccin
demonstr
mucos
immun
lipopeptid
antigen
without
adjuv
monophosphoryl
lipid
mpl
promot
strong
mucos
system
immun
respons
effect
reduc
mtb
burden
mous
model
mtb
infect
support
efficaci
prophylact
vaccin
present
studi
investig
potenti
lipopeptid
base
subunit
vaccin
boost
protect
immun
induc
bcg
preexposur
postexposur
infect
hypothes
lipopeptid
base
subunit
vaccin
could
potenti
use
boost
bcg
prophylact
vaccin
use
immunotherapeut
vaccin
bcg
vaccin
still
infect
individu
intriguingli
preexposur
boost
vaccin
lead
signific
improv
efficaci
bcg
upon
infect
mice
mtb
postexposur
boost
bcg
prime
mice
led
signific
decreas
mtb
bacteri
load
compar
bcg
vaccin
group
associ
increas
immun
respons
local
lung
system
spleen
result
expos
difficulti
encount
design
effect
strategi
boost
bcg
vaccin
provid
new
paradigm
concept
boost
bcg
vaccin
effort
investig
novel
approach
tb
vaccin
anim
experi
use
studi
approv
univers
alberta
anim
care
use
committe
acuc
health
scienc
conduct
accord
guidelin
canadian
council
anim
care
ccac
fiveto
sixweekold
femal
balbc
mice
purchas
charl
river
laboratori
hous
biocontain
bsl
anim
facil
hsla
univers
alberta
synthet
lipopeptid
deriv
mteqqwnfagieaaak
palmit
g
egkqsltklaaawggsgseayqgvqk
palmit
g
sgseayqgvqqkwdatatelnnalqk
palmit
g
tatelnnalqnlartiseagqamask
palmit
g
iseagqamastegnvtgmfak
palmit
g
custom
synthes
genscript
inc
nj
unit
state
lipopeptid
dissolv
dmso
mgml
store
dilut
pb
medium
prior
use
mpl
sigma
aldrich
use
adjuv
ppd
antigen
obtain
staten
serum
institut
denmark
bcg
vaccin
copenhagen
tuberculosi
atcc
rockvil
md
grown
middlebrook
broth
supplement
oleic
acid
albumin
dextros
complex
bd
tween
glycerol
midlog
phase
freez
bacteri
viabil
determin
plate
sampl
middlebrook
medium
supplement
odac
count
number
colonyform
unit
cfu
vaccin
live
bcg
pb
administ
subcutan
sc
base
tail
mous
subunit
boost
immun
mice
administ
intranas
nostril
pool
lipopeptid
contain
lipopeptid
mix
total
absenc
presenc
adjuv
mpl
control
mice
immun
equal
amount
pb
schedul
administr
bcg
shown
figur
preexposur
postexposur
set
mycobacteri
infect
mice
inject
cfumous
mtb
intraven
four
week
mtb
infect
mice
euthan
lung
liver
spleen
remov
asept
individu
homogen
ml
salin
aliquot
taken
organ
homogen
individu
mice
serial
dilut
plate
middlebrook
agar
plate
bd
bioscienc
plate
incub
week
prior
count
coloni
cfu
mtb
obtain
unvaccin
group
individu
mice
differ
experi
rang
lung
liver
spleen
harvest
bal
fluid
cell
lung
lavag
icecold
steril
pb
wtvol
bovin
serum
albumin
bsa
two
pb
wash
fluid
centrifug
rpm
min
rbc
lysi
perform
cell
pellet
rbc
lysi
cell
pellet
resuspend
steril
distil
water
vortex
briefli
immedi
pb
ad
tube
vortex
briefli
volum
made
ml
pb
obtain
lymphocyt
use
stain
supernat
initi
bal
fluid
use
cytokin
analys
cytokin
secret
bal
measur
use
sandwich
elisa
kit
follow
manufactur
protocol
ebiosci
ca
unit
state
dilut
use
sampl
standard
rang
pgml
elisa
plate
read
autom
elisa
plate
reader
fluostar
optima
bmg
labtech
gmbh
ortenberg
germani
antigenspecif
cell
prolifer
assay
perform
use
splenocyt
purifi
nylon
wool
report
previous
us
krishnada
et
al
respect
lipopeptid
use
recal
antigen
concentr
purifi
protein
deriv
mtb
ppd
use
plate
incub
day
cell
puls
thymidin
amersham
h
harvest
filter
paper
level
thymidin
incorpor
dna
prolifer
cell
count
microbeta
trilux
liquid
scintil
counter
perkin
elmer
stimul
indic
calcul
cpm
antigenstimul
culturecpm
medium
stimul
cultur
data
repres
mean
stimul
indic
sd
standard
deviat
triplic
cultur
total
cell
bal
immun
challeng
mice
stain
extracellular
antimous
ebiosci
ca
unit
state
marker
use
establish
procedur
intracellular
cytokin
stain
splenocyt
cultur
day
medium
peptid
pool
lipopeptid
ppd
day
brefeldin
x
ebiosci
ad
cultur
h
subsequ
stain
extracellular
marker
intracellular
cytokin
use
previous
report
procedur
intracellular
grb
stain
x
splenocyt
obtain
mice
stain
extracellular
marker
intracellular
grbalexaflour
without
ex
vivo
stimul
use
previous
report
procedur
sampl
run
lsr
fortessa
sorp
flow
cytomet
analyz
use
facsdiva
softwar
becton
dickinson
mountain
view
ca
unit
state
respect
isotypematch
control
antibodi
use
gate
nonspecif
stain
experi
gate
set
exclud
isotyp
control
antibodi
stain
cell
extracellular
intracellular
stain
experi
data
analyz
use
graphpad
prism
softwar
graphpad
softwar
inc
ca
unit
state
data
present
mean
sd
replic
valu
signific
differ
two
group
two
group
analyz
use
twoway
anova
use
tukey
multipl
comparison
test
p
consid
statist
signific
convent
primeboost
strategi
immun
prime
boost
vaccin
given
prophylact
manner
prevent
infect
occur
howev
besid
examin
role
boost
bcg
vaccin
convent
manner
also
want
examin
boost
use
mtb
infect
set
one
prime
bcg
vaccin
yet
becam
infect
mtb
design
two
primeboost
schedul
figur
b
immun
schedul
preexposur
boost
mice
prime
bcg
vaccin
sc
follow
boost
intranas
day
infect
mtb
subsequ
day
boost
schedul
b
postexposur
boost
mice
prime
bcg
vaccin
sc
follow
infect
mtb
day
boost
intranas
subsequ
day
infect
memori
respons
would
take
week
emerg
howev
want
examin
effect
primari
immun
signific
number
paper
immun
field
use
day
postimmun
evalu
induct
adapt
immun
vast
literatur
suggest
day
immun
humor
cellular
adapt
immun
respons
measur
effect
adjuv
mpl
use
innat
immun
expect
last
day
day
immun
challeng
schedul
euthan
schedul
b
schedul
allow
us
maintain
consist
timefram
initi
bcg
prime
pre
postexposur
boost
schedul
mice
vaccin
bcg
alon
unvaccin
mice
use
control
mice
primeboost
schedul
b
euthan
day
post
infect
mtb
outcom
infect
determin
examin
viabl
count
mtb
lung
liver
spleen
use
coloni
form
unit
cfu
assay
immun
bcgalon
led
reduct
cfu
lung
liver
spleen
compar
unvaccin
control
set
experi
cfu
mtb
obtain
unvaccin
group
individu
mice
differ
experi
rang
lung
liver
spleen
determin
effect
subunit
vaccin
boost
bcg
prime
schedul
calcul
mtb
viabl
count
rel
bcgalon
group
shown
figur
b
boost
subunit
vaccin
preexposur
set
enhanc
protect
bcgalon
base
lung
spleen
liver
figur
fact
mtb
load
slightli
higher
mpl
boost
group
lung
spleen
compar
bcgalon
group
intriguingli
bcgprime
anim
boost
subunit
vaccin
mtb
infect
postexposur
schedul
remark
reduct
pulmonari
extra
pulmonari
bacteri
load
liver
spleen
compar
bcgalon
vaccin
mice
figur
moreov
addit
adjuv
mpl
subunit
vaccin
enhanc
protect
efficaci
booster
vaccin
figur
overal
result
demonstr
subunit
boost
without
mpl
impart
superior
protect
bcg
administ
infect
presenc
cytokin
bal
fluid
reflect
immun
respons
ongo
lung
primari
site
mtb
infect
determin
pulmonari
immun
respons
underli
enhanc
protect
observ
postexposur
boost
next
analyz
concentr
bal
fluid
vaccin
mtbinfect
mice
bal
unvaccin
anim
exhibit
low
level
high
level
figur
b
vaccin
bcg
alon
led
increas
level
decreas
compar
unvaccin
group
howev
interest
chang
bal
cytokin
observ
upon
boost
correl
mtb
load
bcg
prime
mice
boost
subunit
vaccin
infect
mtb
higher
level
lower
level
compar
bcgvaccin
mice
demonstr
increas
protect
immun
figur
contrast
result
show
signific
decreas
level
increas
level
bal
fluid
bcgprime
mice
boost
vaccin
mtb
challeng
compar
bcg
alon
vaccin
anim
figur
signific
differ
level
found
bcg
alon
vaccin
preexposur
boost
group
addit
adjuv
mpl
either
enhanc
effect
cytokin
induc
bal
boost
subunit
vaccin
figur
cell
infiltr
airway
shown
critic
improv
protect
mucos
vaccin
thu
next
sought
determin
cell
infiltr
bal
see
pre
postexposur
subunit
boost
might
modifi
bcgprime
cell
respons
mous
lung
due
presenc
multipl
cell
epitop
bcg
well
subunit
vaccin
chose
examin
gross
chang
total
cell
popul
instead
peptid
epitopespecif
cell
result
obtain
demonstr
frequenc
infiltr
cell
higher
subunit
boost
mice
compar
bcgalon
group
regardless
time
boost
figur
b
contrast
frequenc
cell
doubl
neg
cell
dn
cell
significantli
enhanc
postexposur
boost
group
compar
bcgalon
preexposur
boost
group
figur
iiia
b
strikingli
significantli
higher
frequenc
cell
subset
express
activ
marker
found
postexposur
boost
group
compar
bcgalon
figur
b
frequenc
cell
express
found
compar
preand
postexposur
subunit
boost
figur
iiia
b
inclus
mpl
subunit
vaccin
led
overal
increas
infiltr
cell
bal
irrespect
schedul
boost
figur
overal
data
suggest
boost
bcgprime
respons
subunit
vaccin
result
enhanc
infiltr
activ
cell
bal
select
increas
infiltr
activ
cell
postexposur
boost
schedul
could
least
partial
account
enhanc
protect
bcgalon
next
sought
determin
whether
intranas
boost
subunit
vaccin
differ
schedul
ie
pre
postexposur
distinguish
system
cell
respons
induc
boost
antigen
perform
bulk
cell
prolifer
assay
use
splenocyt
obtain
differ
experiment
group
ex
vivo
stimul
purifi
protein
deriv
ppd
mtb
individu
lipopeptid
subunit
vaccin
result
express
stimul
indic
obtain
divid
count
per
minut
antigenstimul
cultur
correspond
mediumsolv
control
cultur
figur
result
demonstr
unvaccin
group
show
prolifer
respons
ppd
antigen
due
intrins
cell
prime
upon
infect
mtb
mice
bcg
vaccin
led
signific
increas
ppdspecif
prolifer
interestingli
howev
boost
subunit
vaccin
presenc
absenc
adjuv
mpl
lead
signific
differ
ppdspecif
prolifer
also
affect
schedul
boost
figur
b
contrast
respons
ex
vivo
stimul
individu
lipopeptid
compon
subunit
vaccin
remark
figur
b
signific
cell
prolif
respons
lipopeptid
splenocyt
mice
given
boost
infect
compar
bcgvaccin
unvaccin
group
prolif
respons
dramat
increas
mice
given
postexposur
boost
subunit
vaccin
figur
addit
adjuv
mpl
result
enhanc
antigenspecif
prolifer
preexposur
boost
group
result
stronger
enhanc
cell
prolifer
postexposur
boost
group
compar
respect
subunit
group
figur
result
suggest
immun
bcg
possibl
lead
modul
cell
compromis
respons
subunit
vaccin
wherea
boost
given
mtb
infect
abl
reeduc
immun
system
lead
prolif
subunit
vaccineinduc
cell
respons
culmin
improv
efficaci
reduc
mtb
burden
function
qualiti
cell
respons
induc
subunit
vaccin
boost
would
determin
protect
efficaci
abil
boost
bcgprime
respons
observ
postexposur
boost
subunit
vaccin
provid
higher
reduct
mtb
viabl
count
higher
level
bal
higher
prolifer
splenocyt
antigendepend
manner
compar
bcg
vaccin
preexposur
boost
figur
sought
examin
function
attribut
cell
splenocyt
stimul
ex
vivo
ppd
lp
mix
recal
antigen
figur
bulk
splenocyt
cultur
incub
medium
ppd
lp
mix
day
use
determin
intracellular
cytokin
product
cell
flow
cytometri
data
express
medium
control
cultur
correspond
experiment
group
determin
antigen
specificitydepend
induc
cytokin
respons
among
cell
induc
respons
ex
vivo
stimul
ppd
increas
bcgimmun
group
compar
unvaccin
group
unaffect
group
boost
pre
postexposur
group
figur
b
contrast
signific
increas
cell
postexposur
group
compar
preexposur
unvaccin
bcg
vaccin
group
figur
b
interestingli
ppd
recal
group
increas
cell
observ
upon
bcg
vaccin
maintain
upon
boost
schedul
contrast
howev
ex
vivo
stimul
splenocyt
lp
mix
lead
signific
increas
cell
unvaccin
bcgalon
group
suggest
boost
subunit
lead
cell
produc
high
level
figur
b
examin
cytokin
produc
cell
demonstr
entir
differ
interest
pattern
figur
b
respons
ppd
induct
cell
bcg
vaccin
similar
group
irrespect
schedul
boost
contrast
respons
ex
vivo
stimul
lp
mix
postexposur
group
significantli
higher
well
produc
cell
enhanc
group
receiv
mpl
addit
vaccin
figur
b
seem
almost
complet
lack
induct
antigenspecificdepend
cell
preexposur
boost
group
receiv
subunit
vaccin
without
mpl
data
indic
signific
differ
induct
effector
cell
depend
time
subunit
vaccin
given
pre
postexposur
clear
whether
differ
due
immunomodul
induc
bcg
vaccin
overcom
subunit
vaccin
upon
infect
subunit
vaccin
either
abl
amplifi
primari
respons
induc
infect
immunomodul
induc
bcg
vaccin
overcom
product
infect
intracellular
pathogen
like
mtb
besid
effector
cytokin
cytotox
mechan
import
rid
infect
host
cell
bacteria
granzym
b
grb
marker
function
effector
cytotox
cell
nk
nkt
cell
promin
cytotox
lymphocyt
mediat
kill
infect
cell
secret
grb
nk
nkt
cell
classic
consid
innat
immun
cell
recent
also
shown
stimul
upon
antigenbas
vaccin
memori
respons
like
adapt
cell
examin
effect
subunit
vaccin
boost
effector
cytotox
lymphocyt
splenocyt
obtain
mice
examin
grb
express
nk
nkt
cell
without
ex
vivo
restimul
figur
b
intriguingli
percent
cell
express
grb
increas
order
unvaccin
bcg
alon
boost
boost
postexposur
schedul
wherea
preexposur
schedul
boost
led
decreas
compar
bcg
group
figur
b
grb
express
nk
nkt
cell
show
trend
unvaccin
bcg
alon
boost
pre
postexposur
group
figur
b
experi
indic
boost
subunit
vaccin
lead
overal
increas
grbexpress
effector
cytotox
cell
compar
bcg
alon
clearli
urgent
unmet
need
investig
new
vaccineimmunotherapi
approach
tuberculosi
heterolog
primeboost
vaccin
appear
promis
strategi
investig
new
vaccin
approach
howev
despit
increas
focu
last
two
decad
clinic
progress
heterolog
primeboost
strategi
limit
due
insuffici
understand
protect
immun
respons
requir
target
antigen
deliveri
rout
schedul
boost
viral
vector
deriv
boost
vaccin
investig
limit
clinic
success
concern
seriou
side
effect
number
fusion
proteinbas
subunit
vaccin
test
booster
bcg
howev
weak
immunogen
proteinpeptidebas
vaccin
requir
safe
effect
adjuv
pose
issu
earlier
studi
demonstr
lipidmodifi
permiss
cell
epitop
induc
strong
protect
immun
mtb
upon
mucos
intranas
administr
enhanc
addit
adjuv
mpl
premis
subunit
vaccin
may
suffici
induc
broad
multifunct
protect
immun
requir
protect
complex
pathogen
mtb
sought
investig
potenti
boost
supplement
vaccin
prime
bcg
approach
would
stringent
conform
classic
definit
boost
sinc
bcg
vaccin
encompass
antigen
would
rather
provid
expans
concept
primeboost
vaccin
strategi
howev
numer
earlier
exampl
notsosuccess
preclin
clinic
test
bcgprime
heterologousboost
prompt
us
reexamin
approach
unconvent
manner
postexposur
therapeut
vaccin
previous
studi
evalu
bcgvaccin
healthi
individu
tradit
primeboost
vaccin
approach
requir
administr
booster
vaccin
variou
time
prime
vaccin
prevent
infect
time
dose
rout
still
continu
debat
although
bcginduc
immun
known
wane
time
known
good
year
childhood
immun
human
suggest
minor
chang
time
booster
vaccin
may
show
quantifi
differ
scarc
studi
thoroughli
examin
time
boost
homolog
boost
bcg
bcg
prime
demonstr
benefici
effect
compar
heterolog
boost
effect
time
differ
boost
vaccin
variabl
boost
potenti
found
influenc
time
boost
bcgprime
children
wherea
prolong
time
bcg
prime
boost
found
favor
anoth
subunit
vaccin
use
recombin
mycobacteri
adhesin
heparinbind
haemagglutinin
rhbha
specul
repeat
activ
alreadi
activ
cell
may
lead
increas
apoptosi
follow
subunitboost
result
suboptim
booster
effect
observ
peak
bcg
respons
wherea
boost
contractioneffector
memori
phase
cell
respons
may
provid
better
effect
howev
heterolog
boost
antigen
absent
bcg
mechan
may
neither
relev
limit
therefor
may
offer
advantag
due
least
detriment
effect
caus
apoptosi
alreadi
activ
cell
bcg
known
protect
pulmonari
tb
subunit
vaccin
demonstr
promis
efficaci
pulmonari
mtb
infect
given
intranas
sinc
mani
bcgprime
individu
still
develop
activ
mtb
infect
tb
diseas
one
third
world
popul
latent
infect
mtb
desper
need
develop
postexposur
vaccin
tb
experiment
protocol
figur
b
design
test
prophylact
preexposur
therapeut
postexposur
vaccin
mice
prime
bcg
surprisingli
subunit
vaccin
abl
confer
enhanc
protect
preexposur
schedul
except
liver
exhibit
promis
enhanc
protect
postexposur
schedul
compar
bcgalon
group
figur
b
possibl
vaccin
postinfect
also
lead
reduct
mtb
load
bcg
unprim
mice
howev
group
includ
due
experiment
design
focus
bcg
prime
anim
lack
improv
protect
preexposur
schedul
unexpect
earlier
studi
subunit
vaccin
confer
signific
protect
mtb
infect
anticip
least
addit
effect
exact
mechan
discrep
clear
howev
specul
prime
bcg
modul
regul
cell
way
could
overcom
subunit
boost
prior
infect
wherea
upon
infect
either
cell
get
prime
due
de
novo
infect
mtb
get
boost
upon
administr
subunit
vaccin
product
infect
allow
reeduc
recent
thymic
emigr
rte
cell
possibl
investig
futur
studi
shown
mous
model
mtb
infect
recent
thymic
emigr
contribut
peripher
cell
respons
acut
mtb
infect
hand
chronic
infect
mtb
lead
exhaust
antigenspecif
cell
central
toler
major
factor
limit
cell
respons
mtb
infect
infect
mtb
capabl
support
activ
recent
thymic
emigr
open
possibl
reeduc
subunit
booster
vaccin
although
bcg
vaccin
live
vaccin
expect
replic
host
short
durat
day
bcg
prime
subunit
vaccin
preexposur
schedul
studi
expect
lead
exhaust
apoptosi
cell
furthermor
sinc
antigen
present
bcg
vaccin
strain
mechan
blunt
respons
induc
antigen
possibl
prime
bcg
induc
treg
dampen
induct
respons
shown
earlier
bcg
vaccin
trigger
specif
activ
treg
howev
extent
treg
affect
boost
anoth
vaccin
clear
evalu
experi
perform
studi
mice
product
infect
mtb
examin
bal
fluid
cytokin
demonstr
interest
pattern
vs
product
figur
b
suggest
singl
import
cytokin
protect
immun
mtb
role
could
protect
inflammatori
andor
regulatori
compar
healthi
peopl
cell
produc
report
upregul
bal
fluid
pulmonari
tb
patient
indic
probabl
contribut
antimycobacteri
respons
interestingli
postexposur
boost
studi
led
enhanc
level
contrast
preexposur
boost
enhanc
absenc
upregul
level
reduc
proport
exact
cellular
sourc
cytokin
bal
fluid
also
clear
could
innat
andor
adapt
lymphocyt
examin
bal
infiltr
lymphocyt
demonstr
interest
pattern
clear
distinct
preexposur
postexposur
boost
figur
ii
iiia
b
bcg
prime
led
increas
recruit
cell
compar
unvaccin
mice
boost
led
signific
enhanc
doubl
neg
dn
cell
infiltr
bal
postexposur
boost
regimen
reason
enhanc
cell
infiltr
bal
preexposur
boost
schedul
clear
howev
appear
increas
cell
bal
postexposur
boost
may
least
partial
contribut
increas
reduct
mtb
viabl
count
figur
intracellular
pathogen
like
mtb
besid
cytokinemedi
mechan
cytotox
lymphocyt
expect
play
signific
role
remov
infect
host
cell
therebi
clear
infect
interestingli
bcg
vaccin
known
predominantli
induc
cell
attempt
broaden
respons
toward
cell
respons
includ
boost
recombin
adenoviru
vector
contain
b
make
recombin
bcg
amen
induc
cell
respons
includ
multipl
antigen
perfringolysin
bcg
also
known
induc
treg
may
compromis
abil
boost
enhanc
cell
infiltr
preexposur
boost
could
overcom
product
infect
mtb
result
signific
increas
postexposur
boost
postexposur
boost
signific
increas
doubl
neg
cell
bal
express
earli
activ
marker
dn
cell
although
increas
unvaccin
mice
significantli
differ
compar
bcgalon
group
sinc
express
transient
earli
activ
cell
time
experi
could
contribut
seemingli
signific
increas
signific
enhanc
percentag
dn
cell
bal
upon
post
exposur
boost
interest
although
current
studi
clearli
identifi
function
cell
contribut
reduct
mtb
load
doubl
neg
cell
suggest
thymic
extrathym
origin
preval
lung
liver
genit
tract
may
inflammatori
andor
regulatori
potenti
interestingli
respons
live
vaccin
respiratori
infect
intracellular
bacteria
francisella
tularensi
mice
dn
cell
shown
major
respond
cell
dn
cell
shown
produc
earlier
cell
demonstr
featur
antigenexperienc
cell
includ
lower
threshold
stimul
prolifer
cytokin
product
also
contribut
clearanc
infect
shown
limit
expans
dn
cell
result
also
demonstr
reciproc
regul
dn
cell
bal
postexposur
boost
mice
figur
doubl
neg
memori
cell
lung
function
properti
similar
cell
also
shown
react
influenza
viru
infect
shown
express
repres
activ
memori
phenotyp
overal
result
demonstr
enhanc
dn
cell
bal
upon
postexposur
boost
may
contribut
increas
reduct
mtb
load
prolifer
expans
antigenspecif
cell
signatur
activ
adapt
immun
gross
splenocyt
prolifer
assay
recal
respons
purifi
protein
deriv
ppd
show
enhanc
group
compar
bcg
alon
howev
recal
respons
individu
lp
subunit
vaccin
substanti
increas
postexposur
group
compar
preexposur
group
figur
addit
mpl
enhanc
effect
figur
result
demonstr
cell
prolifer
respons
poor
preexposur
group
given
day
bcg
prime
figur
result
contrast
earlier
studi
immun
mice
prime
bcg
show
excel
cell
respons
like
due
immunemodul
induc
prime
bcg
vaccin
observ
prolifer
respons
ppd
recal
affect
pre
postexposur
boost
subunit
compar
bcgalon
group
prolif
respons
lp
becam
highli
exagger
postexposur
boost
indic
subunit
vaccin
effici
boost
bcg
prime
per
se
either
could
reeduc
mtbspecif
respons
infect
product
infect
could
overcom
bcginduc
regulatori
effect
analys
antigendepend
product
cell
ex
vivostimul
splenocyt
bcgalon
subunit
vaccin
boost
group
figur
iia
b
demonstr
clear
superior
postexposur
subunit
vaccin
induc
produc
cell
compar
preexposur
boost
cell
demonstr
effici
effector
intracellular
pathogen
intriguingli
though
also
signific
increas
cell
figur
mous
model
coronaviru
infectioninduc
enceph
produc
cell
demonstr
reflect
cytotox
lymphocyt
superior
effector
cytolyt
function
unlik
product
cell
shown
least
partial
associ
persist
infect
produc
cell
shown
acut
respiratori
infect
influenza
viru
respiratori
syncyti
viru
simian
viru
granzym
b
produc
activ
innat
adapt
cytotox
lymphocyt
determin
cytotox
granul
perforindepend
cytolyt
activ
clearanc
intracellular
pathogen
mtb
would
highli
facilit
activ
cytotox
lymphocyt
conduct
grb
express
analys
splenocyt
directli
obtain
anim
without
ex
vivo
cultur
avoid
nonspecif
ex
vivo
activ
effector
lymphocyt
report
cytokin
stimul
grb
express
cell
even
without
antigen
stimul
examin
intracellular
grb
express
splenocyt
demonstr
boost
subunit
vaccin
increas
grb
express
cell
compar
bcg
vaccin
alon
postexposur
boost
group
preexposur
group
figur
contrast
grb
express
nk
nkt
cell
upregul
follow
bcg
vaccin
compar
unvaccin
group
show
trend
toward
enhanc
boost
pre
postexposur
schedul
figur
result
indic
boost
may
induc
memorylik
effect
nk
nkt
cell
report
homolog
bcg
boost
adult
human
besid
stimul
cell
also
stimul
memori
nk
nkt
cell
express
grb
antimycobacteri
effector
molecul
key
question
attempt
gener
effect
tb
vaccin
qualiti
quantiti
immun
respons
requir
optim
protect
tb
studi
clearli
suggest
mucos
boost
subunit
vaccin
allow
expans
immun
respons
respect
target
mycobacteri
antigen
overal
qualiti
quantiti
compar
bcg
vaccin
alon
lessexplor
crucial
question
time
boost
bcg
prime
studi
shed
import
light
key
question
perhap
partial
help
explain
mani
unsuccess
attempt
direct
toward
primeboost
strategi
tb
vaccin
work
need
determin
detail
reasonsmechan
inabl
preexposur
boost
subunit
vaccin
enhanc
protect
compar
bcg
alon
nevertheless
repres
signific
advanc
demonstr
schedul
subunit
vaccin
boost
postexposur
therefor
reeduc
cell
may
promis
futur
path
toward
success
tb
vaccin
addit
studi
provid
immens
promis
develop
subunit
vaccin
bcgvaccin
individu
still
get
activ
tb
infect
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
